Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYL-1402O vs Avastin in first-line stage IV non-squamous non-small cell lung cancer
2015-005141-32Phase 3Completed
- Sponsor
- Mylan
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MYL-1402O in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mylan. Primary endpoint: Overall response rate (primary). Started Jun 2016; status: completed.
02
Drugs
MYL-1402O
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005141-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005141-32.